Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial
BackgroundSeveral studies have shown that various concentrations of low-concentration atropine can reduce myopia progression and control axial elongation safely and efficiently in children. The aim of this study was to evaluate the effects of 0.02% and 0.01% atropine on ocular biometrics.MethodsCoho...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2023.1095495/full |
| _version_ | 1797951424262307840 |
|---|---|
| author | Ming Wang Can Cui Shi-Ao Yu Ling-ling Liang Jing-Xue Ma Ai-Cun Fu |
| author_facet | Ming Wang Can Cui Shi-Ao Yu Ling-ling Liang Jing-Xue Ma Ai-Cun Fu |
| author_sort | Ming Wang |
| collection | DOAJ |
| description | BackgroundSeveral studies have shown that various concentrations of low-concentration atropine can reduce myopia progression and control axial elongation safely and efficiently in children. The aim of this study was to evaluate the effects of 0.02% and 0.01% atropine on ocular biometrics.MethodsCohort study. 138 and 142 children were randomized to use either 0.02% or 0.01% atropine eye drops, respectively. They wore single-vision (SV) spectacles, with one drop of atropine applied to both eyes nightly. Controls (N = 120) wore only SV spectacles. Ocular and corneal astigmatism were calculated using Thibos vector analysis and split into J0 and J45.ResultsThe changes in cycloplegic spherical equivalent refraction (SER) and axial length (AL) were −0.81 ± 0.52D, −0.94 ± 0.59D, and −1.33 ± 0.72D; and 0.62 ± 0.29 mm, 0.72 ± 0.31 mm, and 0.89 ± 0.35 mm in the 0.02% and 0.01% atropine and control groups, respectively (all P < 0.05). Both anterior chamber depth (ACD) and ocular astigmatism (including J0) increased, and lens power decreased in the three groups (all P < 0.05). However, there were no differences in the changes in ACD, ocular astigmatism, and lens power among the three groups (all P > 0.05). Intraocular pressure (IOP), corneal curvature, ocular astigmatism J45, and corneal astigmatism (including J0 and J45) remained stable over time in the three groups (all P > 0.05). The contributions to SER progression from the changes in AL, lens and corneal power of the three groups were similar (P > 0.05). The contribution of AL change alone to the change in SER was 56.3%, 63.4% and 78.2% in the above corresponding three groups.ConclusionsAfter 2 years, 0.02% and 0.01% atropine had no clinical effects on corneal and lens power, ocular and corneal astigmatism, ACD or IOP compared to the control group. 0.02% and 0.01% atropine helped to control myopia progression mainly by reducing AL elongation. |
| first_indexed | 2024-04-10T22:30:23Z |
| format | Article |
| id | doaj.art-1046d079aee54882ae46dd4cec00ffd4 |
| institution | Directory Open Access Journal |
| issn | 2296-2360 |
| language | English |
| last_indexed | 2024-04-10T22:30:23Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj.art-1046d079aee54882ae46dd4cec00ffd42023-01-17T05:25:39ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602023-01-011110.3389/fped.2023.10954951095495Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trialMing Wang0Can Cui1Shi-Ao Yu2Ling-ling Liang3Jing-Xue Ma4Ai-Cun Fu5Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Ophthalmology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Ophthalmology, Shi Jiazhuang Aier Eye Hospital, Shi Jiazhuang, ChinaDepartment of Ophthalmology, Shi Jiazhuang Aier Eye Hospital, Shi Jiazhuang, ChinaDepartment of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaBackgroundSeveral studies have shown that various concentrations of low-concentration atropine can reduce myopia progression and control axial elongation safely and efficiently in children. The aim of this study was to evaluate the effects of 0.02% and 0.01% atropine on ocular biometrics.MethodsCohort study. 138 and 142 children were randomized to use either 0.02% or 0.01% atropine eye drops, respectively. They wore single-vision (SV) spectacles, with one drop of atropine applied to both eyes nightly. Controls (N = 120) wore only SV spectacles. Ocular and corneal astigmatism were calculated using Thibos vector analysis and split into J0 and J45.ResultsThe changes in cycloplegic spherical equivalent refraction (SER) and axial length (AL) were −0.81 ± 0.52D, −0.94 ± 0.59D, and −1.33 ± 0.72D; and 0.62 ± 0.29 mm, 0.72 ± 0.31 mm, and 0.89 ± 0.35 mm in the 0.02% and 0.01% atropine and control groups, respectively (all P < 0.05). Both anterior chamber depth (ACD) and ocular astigmatism (including J0) increased, and lens power decreased in the three groups (all P < 0.05). However, there were no differences in the changes in ACD, ocular astigmatism, and lens power among the three groups (all P > 0.05). Intraocular pressure (IOP), corneal curvature, ocular astigmatism J45, and corneal astigmatism (including J0 and J45) remained stable over time in the three groups (all P > 0.05). The contributions to SER progression from the changes in AL, lens and corneal power of the three groups were similar (P > 0.05). The contribution of AL change alone to the change in SER was 56.3%, 63.4% and 78.2% in the above corresponding three groups.ConclusionsAfter 2 years, 0.02% and 0.01% atropine had no clinical effects on corneal and lens power, ocular and corneal astigmatism, ACD or IOP compared to the control group. 0.02% and 0.01% atropine helped to control myopia progression mainly by reducing AL elongation.https://www.frontiersin.org/articles/10.3389/fped.2023.1095495/fullmyopiachildrenefficacyocular biometricslow-concentration atropine |
| spellingShingle | Ming Wang Can Cui Shi-Ao Yu Ling-ling Liang Jing-Xue Ma Ai-Cun Fu Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial Frontiers in Pediatrics myopia children efficacy ocular biometrics low-concentration atropine |
| title | Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial |
| title_full | Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial |
| title_fullStr | Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial |
| title_full_unstemmed | Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial |
| title_short | Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial |
| title_sort | effect of 0 02 and 0 01 atropine on ocular biometrics a two year clinical trial |
| topic | myopia children efficacy ocular biometrics low-concentration atropine |
| url | https://www.frontiersin.org/articles/10.3389/fped.2023.1095495/full |
| work_keys_str_mv | AT mingwang effectof002and001atropineonocularbiometricsatwoyearclinicaltrial AT cancui effectof002and001atropineonocularbiometricsatwoyearclinicaltrial AT shiaoyu effectof002and001atropineonocularbiometricsatwoyearclinicaltrial AT linglingliang effectof002and001atropineonocularbiometricsatwoyearclinicaltrial AT jingxuema effectof002and001atropineonocularbiometricsatwoyearclinicaltrial AT aicunfu effectof002and001atropineonocularbiometricsatwoyearclinicaltrial |